Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 30:10:614907.
doi: 10.3389/fonc.2020.614907. eCollection 2020.

Towards Personalization in the Curative Treatment of Gastric Cancer

Astrid E Slagter  1 , Marieke A Vollebergh  2 , Edwin P M Jansen  1 , Johanna W van Sandick  3 , Annemieke Cats  2 , Nicole C T van Grieken  4 , Marcel Verheij  1   5
Affiliations
Review

Towards Personalization in the Curative Treatment of Gastric Cancer

Astrid E Slagter et al. Front Oncol. .

Abstract

Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different worldwide guidelines, include perioperative chemotherapy, pre- or postoperative chemoradiotherapy and postoperative chemotherapy. Although gastric cancer is a heterogeneous disease with respect to patient-, tumor-, and molecular characteristics, the current standard of care is still according to a one-size-fits-all approach. In this review, we discuss the background of the different treatment strategies in resectable gastric cancer including the current standard, the specific role of radiotherapy, and describe the current areas of research and potential strategies for personalization of therapy.

Keywords: future perspectives; gastric cancer; multidisciplinary approach; personalization; radiation oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timeline of different practice-changing randomized trials (–31).
Figure 2
Figure 2
Timeline of different randomized trials that have not led to change of clinical practice (yet) in the curative setting, but have investigated important research questions and/or form the rationale behind ongoing (possibly practice changing) studies (46, 47, 49, 77, 90, 103).
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68(6):394–424. 10.3322/caac.21492 - DOI - PubMed
    1. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol (2008) 38(4):259–67. 10.1093/jjco/hyn017 - DOI - PubMed
    1. Lee KS, Oh DK, Han MA, Lee HY, Jun JK, Choi KS, et al. Gastric cancer screening in Korea: Report on the national cancer screening program in 2008. Cancer Res Treat (2011) 43(2):83–8. 10.4143/crt.2011.43.2.83 - DOI - PMC - PubMed
    1. Leung WK, Wu Ms, Kakugawa Y, Kim JJ, Yeoh Kg, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol (2008) 9(3):279–87. 10.1016/S1470-2045(08)70072-X - DOI - PubMed
    1. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2016) 27(August):v38–49. 10.1093/annonc/mdw350 - DOI - PubMed

LinkOut - more resources